Further clinical trials examining anti-CD45 radio-labelled antibodies currently ongoing include: 131Iodine-BC8 with fludarabine, TBI and allo-HCT in advanced AML and MDS patients ([87], phase II, complete no results posted); 211Astatine-BC8-B10 plus fludarabine, cyclophosphamide and TBI before HCT in non-malignant diseases ([88], phase I/II, recruiting); and 211Astatine-BC8-B10 with fludarabine and TBI prior to HCT in high-risk AML, ALL, MDS or mixed-phenotype acute leukaemia ([89], phase I/II, recruiting). This evidence concerns the gene PTPRC and myelodysplastic syndrome.